Clinical guidelines for the treatment of cancer-related anemia

Jim M. Koeller

    Research output: Contribution to journalReview articlepeer-review

    51 Scopus citations

    Abstract

    Defining clinical guidelines for the treatment of cancer-related anemia requires investigation into causes and characteristics of this malady, uses, benefits, and adverse effects of current treatments; and recognition of currently accepted guidelines set forth by the American College of Physicians and the American Association of Blood Banks. Anemia, the most common hematologic abnormality in patients with cancer, originates from a variety of causes, including occult blood loss, hypoproliferation, and hemolysis, and often involves more than one mechanism. Clinical manifestations include fatigue, dyspnea, tachycardia, dizziness, anorexia, and hypersensitivity to cold. Although the majority of cancer-related anemias are hypoproliferative, establishing their pathophysiology in individual patients is critical to effective treatment. Anemia usually, but not always, resolves with successful treatment of underlying disease. Symptomatic relief can be managed in accordance with established treatment guidelines.

    Original languageEnglish (US)
    Pages (from-to)156-169
    Number of pages14
    JournalPharmacotherapy
    Volume18
    Issue number1
    StatePublished - Jan 1 1998

    ASJC Scopus subject areas

    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Clinical guidelines for the treatment of cancer-related anemia'. Together they form a unique fingerprint.

    Cite this